Background
Despite the advances and strides that modern medicine has made, prostate cancer treatment options remain to be fairly reserved.
However, the day is finally here that more methods of treatment could be explored especially for tough and persistent prostate cancer cases.
According to new revolutionary research in the field of cancer research led by The Institute of Cancer Research, London, a drug combination could effectively block two cancer growth signals at once in this type of cancer.
What this means is that this drug combination is effective for men who suffer from aggressive tumor growth and those who lack the PTEN gene which is a tumor suppressor.
The surprising findings:
These new findings published by the lancet show promising results in combining ipatasertib plus abiraterone plus prednisone/prednisolone when it comes to treating prostate cancer.
The IPATential150 study varied its data in more than two dozen countries with 1,101 patients half of which lack the PTEN gene.
The result shows that combining ipatasertib with abiraterone and prednisolone had reduced the death risk by 23 percent compared to the placebo plus abiraterone plus prednisone/prednisolone.
Moreover, almost two-thirds of patients who lacked the PTEN gene which was useful against the tumors saw their tumor getting smaller compared to those in the group that took placebo plus abiraterone plus prednisone/prednisolone where only 39% of patients reported smaller tumors.
What’s even more promising is that the complete remission rate more than tripled with the group that combined Ipatasertib.
No sign of the disease was found in 19 percent of the patients that combined the drug whereas only 6 percent of the patients recovered taking placebo plus abiraterone plus prednisone/prednisolone.
Why this drug combination works:
A follow-up study is required to fully test the safety and efficiency of this method.
However, the findings show a clear win for combing Ipatasertib with these two drugs. It also shows that there is hope for men who are suffering from aggressive and relentless tumors.
The way that this works is by blocking the signals that prompt the growth of tumors.
This issue is something that men who suffer from prostate cancer who lack the PTEN gene fear.
However, with these new findings, it is highly likely that we are going to see a significant drop in mortality rates for prostate cancer as well as increased recovery rates.
Better hope for the future:
Prostate cancer is the number one most common cancer that men suffer from.
Over a million cases worldwide every year could see new hope for the future thanks to this new study that offers a new way to treat prostate cancer.
Prostate cancer is a looming threat and danger to all men especially those who are prone to getting it.
Now with the new advances in science, we can finally see the light at the end of the tunnel and keep our hopes high.
Talk to us so see if we can help you to actually get the most advanced treatments
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
References:
- Sweeney C, Bracarda S, Sternberg CN et al. Ipatasertib and abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): multicenter, randomized, double-blind, phase 3 study. 2021: 398 (10295); 131-142. doi: 10.1016 / S0140-6736 (21) 00580-8
- Rawla, P. (2019). Epidemiology of Prostate Cancer. World Journal of Oncology, 10(2), 63–89. doi:10.14740/wjon1191
